Zivo Bioscience, Inc.: management transactions · United States · SEC (Form 4)

About Zivo Bioscience, Inc.

Zivo Bioscience, Inc. is a United States-based research and development company listed on NASDAQ under the ticker ZIVOW. For international investors, it is best understood as a small-cap biotech/agritech platform whose core value proposition is built around proprietary freshwater algae strains and the development of natural bioactive molecules. The company’s public disclosures describe it as a Nevada corporation with operational roots in the Michigan area, including Bloomfield Hills and Keego Harbor, and its long-term strategy has centered on translating algae science into commercial products, licensing opportunities, and strategic partnerships. Zivo’s business model is multi-layered. Its near-term focus is on nutritional compounds, food ingredients, and functional food applications derived from its proprietary algal biomass and extracts. Management has highlighted potential benefits such as supporting healthy cholesterol balance, immune function, muscle recovery, and joint health. In parallel, the company is pursuing more advanced product opportunities in human health, animal health, and pharmaceutical-oriented applications, where its bioactive molecules may be developed into nutraceutical, biologic, or medicinal candidates. A third pillar is its agtech vision: Zivo has also promoted a large-scale microalgae farm concept designed for warm-temperate and semi-tropical regions, intended to create a scalable production base for its proprietary strains and to support a broader supply chain. From a competitive standpoint, Zivo operates in a niche where scientific validation, intellectual property, and commercialization execution matter more than scale today. The company competes indirectly with plant-based ingredient suppliers, specialty nutrition companies, algae technology developers, and early-stage biotech firms pursuing immune and inflammatory health solutions. Its potential differentiation lies in a proprietary strain portfolio, a “natural / non-GMO / sustainable” positioning, and the ability to span multiple addressable markets rather than relying on a single product category. However, the investment case remains highly execution-dependent, and the company’s commercial scale is still limited relative to established food, ingredient, and biotech peers. Recent highlights include ongoing communication around the commercialization of proprietary algal biomass as a human food or food ingredient, continued investor-relations activity, and multiple SEC filings, including Form 4 insider transaction reporting. These disclosures underscore that ZIVOW remains a closely watched micro-cap NASDAQ name whose profile is driven by R&D milestones, regulatory filings, partnership developments, and the company’s ability to convert algae-based science into repeatable revenue streams in the United States and beyond.